A systematic review of clinical practice guidelines on the use of low molecular weight heparin and fondaparinux for the treatment and prevention of venous thromboembolism: Implications for research and policy decision-making

• Published in: PloS one Vol. 13; no. 11; p. e0207410
• Main Authors: Johnston, Amy, Hsieh, Shu-Ching, Carrier, Marc, Kelly, Shannon E, Bai, Zemin, Skidmore, Becky, Wells, George A
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 09.11.2018; Public Library of Science (PLoS)
• Subjects: Anticoagulants; Clinical decision making; Clinical medicine; Clinical practice guidelines; Comparative studies; Decision Making; Domains; Female; Fondaparinux - adverse effects; Fondaparinux - therapeutic use; Guidelines; Heart; Heparin; Heparin, Low-Molecular-Weight - adverse effects; Heparin, Low-Molecular-Weight - therapeutic use; Humans; Low molecular weights; Male; Medicine and Health Sciences; Methods; Modernization; Molecular weight; Morbidity; Patient safety; Patients; Physicians; Practice Guidelines as Topic; Prescription drug plans; Prescription drugs; Quality assessment; Research methodology; Systematic review; Thromboembolism; Thrombosis; Venous Thromboembolism - prevention & control; Canada; Ottawa Ontario Canada

Venous thromboembolism (VTE) is a major global cause of morbidity and mortality. Low molecular weight heparin (LMWH) and fondaparinux (FDP) are frequently used to treat and prevent VTE and have a variety of safety and practical advantages over other anticoagulants, including use in outpatient settin...